Bicara Therapeutics Inc. (BCAX) announced the pricing of its initial public offering of 17.50 million shares of its common stock at a public offering price of $18.00 per share.
Bicara Therapeutics' shares are expected to begin trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol "BCAX." The offering is expected to close on September 16, 2024.
In addition, Bicara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2.625 million shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Bicara Therapeutics.
Bicara Therapeutics said it expects the gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Bicara Therapeutics, to be about $315.00 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock.
For comments and feedback: editorial@rttnews.com